Inhibitors targeting the LFA-1/ICAM-1 cell-adhesion interaction: design and mechanism of action
- PMID: 18781967
- DOI: 10.2174/138161208785740225
Inhibitors targeting the LFA-1/ICAM-1 cell-adhesion interaction: design and mechanism of action
Abstract
Leukocyte-function associated antigen-1 (LFA-1) is an alpha(L)beta(2) chain integrin expressed on the surface of endothelial cells that modulates the behavior of leukocytes by mediating their adhesion to other cells through its interaction to cell-surface ligands. The most important ligand of LFA-1 is ICAM-1 which is expressed on the surface of endothelial cells. The interaction between LFA-1 and ICAM-1 is involved in inflammatory responses and is therefore implicated in inflammatory pathologies and autoimmune diseases; and, in addition, it is involved in many cancer processes. In light of this, there is great interest in developing small molecule, orally available, inhibitors of the LFA-1/ICAM-1 interaction. A structurally diverse collection of small molecule inhibitors has been characterized and developed either to bind the IDAS site of the alpha(L) I-domain or to the MIDAS of the beta2 I-like domain. In this review, a summary of the structure and regulation of LFA-1 will be given, followed by a description of the different classes of inhibitors that have been described to date.
Similar articles
-
Cellular activation of leukocyte function-associated antigen-1 and its affinity are regulated at the I domain allosteric site.J Immunol. 2001 Aug 1;167(3):1431-9. doi: 10.4049/jimmunol.167.3.1431. J Immunol. 2001. PMID: 11466362
-
The I domain of integrin leukocyte function-associated antigen-1 is involved in a conformational change leading to high affinity binding to ligand intercellular adhesion molecule 1 (ICAM-1).J Biol Chem. 1998 Oct 16;273(42):27396-403. doi: 10.1074/jbc.273.42.27396. J Biol Chem. 1998. PMID: 9765268
-
The second domain of intercellular adhesion molecule-1 (ICAM-1) maintains the structural integrity of the leucocyte function-associated antigen-1 (LFA-1) ligand-binding site in the first domain.Biochem J. 2000 Oct 1;351(Pt 1):79-86. doi: 10.1042/0264-6021:3510079. Biochem J. 2000. PMID: 10998349 Free PMC article.
-
Targeting ICAM-1/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors.Peptides. 2003 Mar;24(3):487-501. doi: 10.1016/s0196-9781(03)00083-4. Peptides. 2003. PMID: 12732350 Review.
-
Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases.Med Res Rev. 2002 Mar;22(2):146-67. doi: 10.1002/med.10001. Med Res Rev. 2002. PMID: 11857637 Review.
Cited by
-
p38MAPK inhibition: a new combined approach to reduce neuroblastoma resistance under etoposide treatment.Cell Death Dis. 2013 Apr 11;4(4):e589. doi: 10.1038/cddis.2013.118. Cell Death Dis. 2013. PMID: 23579276 Free PMC article.
-
A nomogram model to predict the portal vein thrombosis risk after surgery in patients with pancreatic cancer.Front Surg. 2023 Dec 19;10:1293004. doi: 10.3389/fsurg.2023.1293004. eCollection 2023. Front Surg. 2023. PMID: 38169674 Free PMC article.
-
Inhibition of protein kinase C isozymes causes immune profile alteration and possibly decreased tumorigenesis in bladder cancer.Am J Cancer Res. 2023 Aug 15;13(8):3832-3852. eCollection 2023. Am J Cancer Res. 2023. PMID: 37693140 Free PMC article.
-
Receptor-mediated targeted drug delivery systems for treatment of inflammatory bowel disease: Opportunities and emerging strategies.Acta Pharm Sin B. 2021 Sep;11(9):2798-2818. doi: 10.1016/j.apsb.2020.11.003. Epub 2020 Nov 7. Acta Pharm Sin B. 2021. PMID: 34589398 Free PMC article. Review.
-
ICAM-1 suppresses tumor metastasis by inhibiting macrophage M2 polarization through blockade of efferocytosis.Cell Death Dis. 2015 Jun 11;6(6):e1780. doi: 10.1038/cddis.2015.144. Cell Death Dis. 2015. PMID: 26068788 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
